Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.15 -2.9%	$19.68	$10.21 ▼ $25.67	$4.34B	0.43	3.67 million shs	233,497 shs
ELVN Enliven Therapeutics	$22.59 -1.8%	$19.77	$13.30 ▼ $30.03	$1.12B	0.83	300,274 shs	130,454 shs
KRYS Krystal Biotech	$148.43 -1.3%	$135.59	$122.80 ▼ $219.34	$4.29B	0.67	286,396 shs	56,035 shs
MTSR Metsera	$41.81 -1.6%	$28.91	$12.30 ▼ $46.43	$4.39B	N/A	902,129 shs	373,410 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+0.92%	+4.47%	-10.24%	-15.67%	+46.17%
ELVN Enliven Therapeutics	+2.45%	+17.41%	+4.97%	+34.90%	-7.03%
KRYS Krystal Biotech	+1.51%	+7.64%	+9.73%	-11.07%	-25.95%
MTSR Metsera	+8.12%	+49.59%	+44.55%	+147.49%	+4,246,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.9373 of 5 stars	3.7	1.0	0.0	0.0	3.1	2.5	3.1
ELVN Enliven Therapeutics	2.7974 of 5 stars	3.5	2.0	0.0	0.0	2.5	4.2	0.0
KRYS Krystal Biotech	4.658 of 5 stars	3.5	1.0	0.0	4.7	3.0	3.3	1.9
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	52.48% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	82.38% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	44.01% Upside
MTSR Metsera	3.00	Buy	$55.00	31.55% Upside

Current Analyst Ratings Breakdown

Latest ELVN, MTSR, ADMA, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.16	$0.53 per share	34.20	$1.48 per share	12.26
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
KRYS Krystal Biotech	$290.52M	14.77	$4.65 per share	31.95	$32.90 per share	4.51
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.37	26.30	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	35.72	14.73	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ELVN, MTSR, ADMA, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
ELVN Enliven Therapeutics	N/A	21.07	21.06
KRYS Krystal Biotech	N/A	9.65	9.27
MTSR Metsera	N/A	6.55	6.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ELVN Enliven Therapeutics	95.08%
KRYS Krystal Biotech	86.29%
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.70%
ELVN Enliven Therapeutics	25.90%
KRYS Krystal Biotech	13.70%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	229.90 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A

ELVN, MTSR, ADMA, and KRYS Headlines

Recent News About These Companies

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

July 14 at 11:20 AM | finance.yahoo.com

Alphabet Inc. Takes $135.06 Million Position in Metsera Inc. (NASDAQ:MTSR)

July 14 at 6:56 AM | marketbeat.com

Metsera (NASDAQ:MTSR) Sets New 52-Week High - What's Next?

July 11, 2025 | marketbeat.com

Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

July 10, 2025 | zacks.com

Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why

July 10, 2025 | zacks.com

Metsera Clears Key Benchmark, Hitting 90-Plus RS Rating

July 9, 2025 | msn.com

Metsera (NASDAQ:MTSR) Trading Up 6.3% - What's Next?

July 9, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Stock Price Up 10.3% - Here's Why

July 2, 2025 | marketbeat.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Nasdaq

June 26, 2025 | nasdaq.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

June 24, 2025 | zacks.com

Metsera (NASDAQ:MTSR) Trading Down 6.3% - What's Next?

June 23, 2025 | marketbeat.com

Wells Fargo Initiates Coverage of Metsera (MTSR) with Overweight Recommendation

June 20, 2025 | msn.com

Metsera (NASDAQ:MTSR) Coverage Initiated by Analysts at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Trading 6.4% Higher - Still a Buy?

June 18, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Gap Up - Time to Buy?

June 16, 2025 | marketbeat.com

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review

June 12, 2025 | seekingalpha.com

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results

June 11, 2025 | msn.com

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med

June 11, 2025 | medcitynews.comM

Metsera extends gains after early-stage trial data for obesity therapy

June 10, 2025 | msn.com

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating

June 10, 2025 | msn.com

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 10, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN, MTSR, ADMA, and KRYS Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.14 -0.54 (-2.86%)

As of 10:40 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Enliven Therapeutics NASDAQ:ELVN

$22.59 -0.41 (-1.78%)

As of 10:40 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Krystal Biotech NASDAQ:KRYS

$148.43 -1.98 (-1.32%)

As of 10:40 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Metsera NASDAQ:MTSR

$41.81 -0.66 (-1.55%)

As of 10:21 AM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time